Drug resistance in leishmaniasis: Newer developments.

Area of Science:

• Parasitology
• Infectious Diseases
• Drug Discovery

Background:

• Leishmaniasis is a significant global public health issue, transmitted by vectors.
• Chemotherapy is the primary treatment due to the absence of vaccines and effective vector control.
• Antimonials, long-standing first-line treatment, face increasing drug resistance.

Purpose of the Study:

• To review current literature on anti-leishmanial drug resistance.
• To explore newer drug discovery efforts for leishmaniasis.
• To understand emerging drug resistance mechanisms.

Main Methods:

• Comprehensive literature search of PubMed, Medline, and Google Scholar.
• Review of studies on anti-leishmanial drug resistance and new drug development.
• Analysis of identified drug resistance mechanisms.

Main Results:

• Emergence of resistance to antimonials is a critical challenge.
• Several newer anti-leishmanial drugs have been identified but have limited use.
• High cost, toxicity, and existing resistance limit the application of newer drugs.
• Recent identification of novel drug resistance mechanisms offers potential for future drug design.

Conclusions:

• Addressing anti-leishmanial drug resistance requires continuous research and development.
• Understanding new resistance mechanisms is key to designing next-generation therapies.
• Future drug development should focus on overcoming resistance, cost, and toxicity issues.